Collaborative Arrangement, Future Fixed Upfront Payments

No definition available.

Name:	mrk_CollaborativeArrangementFutureFixedUpfrontPayments
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Milestone Payments, Regulatory

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsMilestonePaymentsRegulatory
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Rights and Obligations, Milestone Payments, Sales-Based

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsMilestonePaymentsSalesBased
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Upfront Payments Received Recognized As Revenue

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementUpfrontPaymentsReceivedRecognizedAsRevenue
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483154/926-20-50-5

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	srt_ProductOrServiceAxis=mrk_KoselugoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mrk_LicensesAndOtherMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_LynparzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=mrk_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2025	Sep. 30, 2025	Sep. 30, 2025	Sep. 30, 2024	Jan. 31, 2028	Jan. 31, 2027	Jan. 31, 2026
Koselugo \| Licenses and Other
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Finite-lived intangible assets		$ 41,000,000	$ 41,000,000
Lynparza \| Licenses and Other
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Finite-lived intangible assets		926,000,000	926,000,000
AstraZeneca \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payments recognized as revenue			150,000,000
Sales based milestone payments			700,000,000
AstraZeneca \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Alliance revenue - Koselugo
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payments recognized as revenue		150,000,000
Aggregate, regulatory milestones payments, maximum		75,000,000	75,000,000
Sales milestone payments		235,000,000	235,000,000
AstraZeneca \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Alliance revenue - Koselugo \| Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future fixed upfront payments received					$ 100,000,000	$ 150,000,000	$ 150,000,000
AstraZeneca \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Koselugo
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payments recognized as revenue		50,000,000	50,000,000
Sales based milestone payments			100,000,000
AstraZeneca \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Koselugo \| Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payments recognized as revenue	$ 50,000,000
AstraZeneca \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Lynparza
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate, regulatory milestones payments, maximum		0	0
Sales milestone payments		$ 2,000,000,000.0	2,000,000,000.0
Sales based milestone payments			$ 600,000,000
Regulatory milestone payments				$ 245,000,000